Thalidomide and neurotrophism.

Area of Science:

• Developmental Biology
• Teratology
• Orthopedic Pathology

Background:

• The thalidomide disaster highlighted severe limb malformations (dysmelia).
• Previous studies by Henkel and Willert analyzed skeletal deformities in long bones and extremities.
• This study re-examines Willert's material to understand the mechanism of thalidomide-induced skeletal reduction.

Purpose of the Study:

• To investigate the underlying cause of skeletal reduction in thalidomide embryopathy.
• To determine if thalidomide affects bone quality or quantity.
• To correlate skeletal findings with neurological involvement.

Main Methods:

• Review of original histological slides and radiographs from 30 children with thalidomide exposure.
• Analysis of hand and foot radiographs (19 and 4 cases, respectively).
• Histological examination of musculoskeletal tissues.

Main Results:

• Verified original findings: radial ray reduction in hands, foot spared until later stages.
• Hand bone reduction (aplasia/hypoplasia) correlated with C6 sensory nerve involvement.
• Foot deformities included toe reduction (rare) and hallux polydactyly (L5 sclerotome) associated with absent tibia (L4 sclerotome).
• Histology showed unremarkable mesenchymal components but abnormal bony architecture, indicating a discordance between microscopic and macroscopic findings.
• No evidence of necrosis or vascular pathology was observed.

Conclusions:

• The primary issue in thalidomide embryopathy is an abnormal quantity, not quality, of mesenchyme.
• Neurotrophic disruption due to sensorineural injury in the embryo alters mesenchymal cell proliferation.
• Limb malformations result from altered mesenchymal mass, with normal histological differentiation occurring later.
• The fundamental pathology originates in the nervous system, not the skeleton itself.